Crossmark

Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) – a multicenter, randomized, controlled, open-label investigator-initiated trial

Crossref DOI link: https://doi.org/10.1186/s12885-024-12693-w

Published Online: 2024-08-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schmidt, Constantin

Zapf, Antonia

Ozga, Ann-Kathrin

Canbay, Ali

Denzer, Ulrike

De Toni, Enrico N.

Lohse, Ansgar W.

Schulze, Kornelius

Rösch, Thomas

Stein, Alexander

Wege, Henning

von Felden, Johann
Funding

Funding for this research was provided by:

Universitätsklinikum Hamburg-Eppendorf (UKE)
License Information

Text and Data Mining valid from 2024-08-01

Version of Record valid from 2024-08-01
More Information

Article History

Received: 3 May 2024

Accepted: 24 July 2024

First Online: 1 August 2024

Declarations

:

: The ACTICCA-2 trial was approved and consented by the local ethics committee of the Ärztekammer Hamburg (PV number 2024-101232-BO-ff) and will be reviewed individually for each participating center at the respective local ethics committee. The study is registered with ClinicalTrials.gov (NCT06175845) and Arbeitsgemeinschaft Internistische Onkologie (AIO, AIO-HEP-0323).

: Not applicable as this manuscript does not contain any data from individuals.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below